• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

    1/31/22 4:15:00 PM ET
    $GMDA
    $KLTR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $GMDA alert in real time by email

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Class II Directors.

    "We are very excited to be adding these accomplished leaders to our Board as we continue to advance our robust pipeline of advanced cell therapies," said Julian Adams, Ph.D., Chief Executive Officer of Gamida Cell. "Anat and Naama's expertise further strengthens the scientific and financial capabilities on our board, which is crucial to our mission to create cures for people living with serious diseases."

    Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Dr. Cohen-Dayag is President and Chief Executive Officer and a member of the Board of Directors of Compugen Ltd. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company's computational discovery platforms. Prior to Compugen, Dr. Cohen-Dayag served as Head of R&D and was a member of the executive management team of Mindsense Biosystems Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.

    Dr. Naama Halevi-Davidov has over 25 years of financial experience in the technology sector, holding various executive leadership roles. Dr. Halevi-Davidov served as Chief Financial Officer of Kaltura, Inc., a global software company from 2012 through 2017. Dr. Halevi-Davidov's leadership saw the company through its global expansion, raising over $100M in funding, overseeing acquisitions, and managing revenue growth from zero to tens of millions of dollars. In recent years, Dr. Halevi-Davidov has served as a strategic financial advisor to a number of growing Hi-tech companies, including Healthy IO Ltd., a digital healthcare company and Joytunes Ltd., a wellbeing education app. Dr. Halevi-Davidov now serves on the Board of Kaltura, Inc. (NASDAQ:KLTR), is Chair of the Compensation Committee and a member of the Company's Audit Committee. Dr. Halevi-Davidov is a Certified Public Accountant in Israel. She received a Ph.D. in Strategy, a Master's in Business Administration and a Bachelor of Arts in Accounting and Economics all from Tel Aviv University.

    About Gamida Cell

    Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005070/en/

    Get the next $GMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMDA
    $KLTR

    CompanyDatePrice TargetRatingAnalyst
    Kaltura Inc.
    $KLTR
    12/20/2023$2.00 → $1.50Equal Weight → Underweight
    Wells Fargo
    Kaltura Inc.
    $KLTR
    4/17/2023$2.75 → $1.75Neutral → Underperform
    BofA Securities
    Kaltura Inc.
    $KLTR
    9/13/2022Sector Weight
    KeyBanc Capital Markets
    Kaltura Inc.
    $KLTR
    2/24/2022$5.50 → $2.50Hold
    Deutsche Bank
    Kaltura Inc.
    $KLTR
    2/24/2022$7.00 → $3.00Overweight
    Keybanc
    Kaltura Inc.
    $KLTR
    2/24/2022$15.00 → $8.00Buy
    Needham
    Kaltura Inc.
    $KLTR
    2/23/2022$12.00 → $3.00Buy → Neutral
    BofA Securities
    Kaltura Inc.
    $KLTR
    2/23/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $GMDA
    $KLTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Doherty John N. sold $29,350 worth of shares (17,367 units at $1.69), decreasing direct ownership by 1% to 1,534,820 units (SEC Form 4)

      4 - KALTURA INC (0001432133) (Issuer)

      4/8/25 12:57:10 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Chief Financial Officer Doherty John N. sold $8,914 worth of shares (4,495 units at $1.98), decreasing direct ownership by 0.29% to 1,552,187 units (SEC Form 4)

      4 - KALTURA INC (0001432133) (Issuer)

      3/6/25 2:50:41 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Chief Financial Officer Doherty John N. sold $279,540 worth of shares (113,634 units at $2.46), decreasing direct ownership by 7% to 1,556,682 units (SEC Form 4)

      4 - KALTURA INC (0001432133) (Issuer)

      3/5/25 11:12:25 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology

    $GMDA
    $KLTR
    Financials

    Live finance-specific insights

    See more
    • Kaltura Announces Financial Results for First Quarter 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. ("Kaltura" or the "Company"), the video experience cloud, today announced financial results for the first quarter ended March 31, 2025, as well as outlook for the second quarter and full year 2025. "We surpassed our guidance for the first quarter, delivering record total and subscription revenue, as well as significant Net loss improvement on a GAAP basis, and on a non-GAAP basis - a record positive Adjusted net income, Adjusted EBITDA, and earnings profitability per share. We also posted record ARR and the highest net dollar retention rate since the first quarter of 2022," said Ron Yekutiel, Co-founder, Chairman, President and Ch

      5/8/25 7:00:00 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura to Announce Financial Results for First Quarter 2025 on Thursday, May 8, 2025

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Kaltura (NASDAQ:KLTR), the Video Experience Cloud, today announced it will release its first quarter financial results for the period ended March 31, 2025, before market open on Thursday, May 8, 2025. Management will host a conference call to review the Company's first quarter 2025 financial results and discuss the financial outlook. Date:Thursday, May 8, 2025Time:8:00 a.m. ETUnited States/Canada Toll Free:1-877-407-0789International Toll:+1-201-689-8562   A live and archived webcast will be available in the Investor Relations section of Kaltura's website at: https://investors.kaltura.com/news-and-events/events About KalturaKaltura's mis

      4/21/25 4:05:00 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura Announces Financial Results for Fourth Quarter and Full Year 2024

      NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. ("Kaltura" or the "Company"), the video experience cloud, today announced financial results for the fourth quarter and full year ended December 31, 2024, as well as outlook for first quarter and full year 2025. "We surpassed our guidance for the fourth quarter, delivering record total and subscription revenue, as well as the highest Adjusted EBITDA since the second quarter of 2020, fueled by record high gross margin. We also posted sequential and year-over-year growth in gross and net dollar retention rates, and in new bookings for the third quarter in a row," said Ron Yekutiel, Co-founder, Chairman, President and Chief Exe

      2/20/25 7:00:00 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology

    $GMDA
    $KLTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kaltura Inc.

      SC 13G/A - KALTURA INC (0001432133) (Subject)

      11/13/24 11:13:36 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Kaltura Inc. (Amendment)

      SC 13D/A - KALTURA INC (0001432133) (Subject)

      5/9/24 8:34:50 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      4/1/24 5:49:42 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    $KLTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

      For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

      4/17/23 1:02:15 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    $KLTR
    SEC Filings

    See more

    $GMDA
    $KLTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GMDA
    $KLTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Kaltura Inc.

      10-Q - KALTURA INC (0001432133) (Filer)

      5/8/25 9:31:32 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KALTURA INC (0001432133) (Filer)

      5/8/25 7:11:34 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form DEFA14A filed by Kaltura Inc.

      DEFA14A - KALTURA INC (0001432133) (Filer)

      4/30/25 5:01:26 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura Announces Financial Results for First Quarter 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. ("Kaltura" or the "Company"), the video experience cloud, today announced financial results for the first quarter ended March 31, 2025, as well as outlook for the second quarter and full year 2025. "We surpassed our guidance for the first quarter, delivering record total and subscription revenue, as well as significant Net loss improvement on a GAAP basis, and on a non-GAAP basis - a record positive Adjusted net income, Adjusted EBITDA, and earnings profitability per share. We also posted record ARR and the highest net dollar retention rate since the first quarter of 2022," said Ron Yekutiel, Co-founder, Chairman, President and Ch

      5/8/25 7:00:00 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura to Announce Financial Results for First Quarter 2025 on Thursday, May 8, 2025

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Kaltura (NASDAQ:KLTR), the Video Experience Cloud, today announced it will release its first quarter financial results for the period ended March 31, 2025, before market open on Thursday, May 8, 2025. Management will host a conference call to review the Company's first quarter 2025 financial results and discuss the financial outlook. Date:Thursday, May 8, 2025Time:8:00 a.m. ETUnited States/Canada Toll Free:1-877-407-0789International Toll:+1-201-689-8562   A live and archived webcast will be available in the Investor Relations section of Kaltura's website at: https://investors.kaltura.com/news-and-events/events About KalturaKaltura's mis

      4/21/25 4:05:00 PM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura Announces Stock Repurchase Program

      NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. ("Kaltura" or the "Company") (NASDAQ:KLTR), the Video Experience Cloud, today announced that its Board of Directors has authorized a refreshed stock repurchase program for up to $15 million of the Company's common stock. "Our renewed repurchase authorization underscores the Board's continued confidence in our long-term strategy and its belief that our current share price continues to be undervalued relative to our long-term opportunity. We remain confident in our ability to continue to generate positive operating cash flow and are committed to strategically deploying capital where we believe it can generate shareholder value," sai

      3/21/25 9:15:00 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Kaltura from Equal Weight to Underweight and set a new price target of $1.50 from $2.00 previously

      12/20/23 6:55:43 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • Kaltura downgraded by BofA Securities with a new price target

      BofA Securities downgraded Kaltura from Neutral to Underperform and set a new price target of $1.75 from $2.75 previously

      4/17/23 7:30:39 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology
    • KeyBanc Capital Markets initiated coverage on Kaltura

      KeyBanc Capital Markets initiated coverage of Kaltura with a rating of Sector Weight

      9/13/22 7:26:21 AM ET
      $KLTR
      Computer Software: Prepackaged Software
      Technology

    $GMDA
    $KLTR
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)